Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

Introduction to Hemostasis

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Impaired fibrinolysis and the risk for coronary heart disease.

Circulation·1996

Same author

Characterization of the murine plasminogen/urokinase-type plasminogen-activator system.

European journal of biochemistry·1996

Same author

Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling.

Circulation·1996

Same author

A pilot study on bolus administration of recombinant staphylokinase for coronary artery thrombolysis.

Thrombosis and haemostasis·1996

Same author

Role of tissue factor in embryonic blood vessel development.

Nature·1996

Same author

Effects of deletion of the carboxyl-terminal domain of ApoA-I or of its substitution with helices of ApoA-II on in vitro and in vivo lipoprotein association.

The Journal of biological chemistry·1996

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

The tissue-type plasminogen activator story.

D Collen¹, H R Lijnen

¹Center for Molecular and Vascular Biology, University of Leuven, Campus Gasthuisberg, O & N 1, Herestraat 49 Box 911, B-3000 Leuven, Belgium. desire.collen@med.kuleuven.be

Arteriosclerosis, Thrombosis, and Vascular Biology

|July 17, 2009

Summary

Tissue-type plasminogen activator (t-PA) evolved from cell culture purification to recombinant expression. Large trials confirmed its therapeutic benefit as a fibrin-specific thrombolytic agent.

More Related Videos

Improved Method for the Preparation of a Human Cell-based, Contact Model of the Blood-Brain Barrier

Improved Method for the Preparation of a Human Cell-based, Contact Model of the Blood-Brain Barrier

Published on: November 12, 2013

Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus

Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus

Published on: June 2, 2023

Related Experiment Videos

Last Updated: Jun 21, 2026

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Improved Method for the Preparation of a Human Cell-based, Contact Model of the Blood-Brain Barrier

Improved Method for the Preparation of a Human Cell-based, Contact Model of the Blood-Brain Barrier

Published on: November 12, 2013

Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus

Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus

Published on: June 2, 2023

Area of Science:

Biochemistry
Molecular Biology
Cardiovascular Medicine

Background:

Tissue-type plasminogen activator (t-PA) is a crucial enzyme in fibrinolysis.
Developing t-PA as a targeted thrombolytic agent required significant scientific advancements.

Observation:

Early development involved purifying human t-PA from melanoma cell lines.
Understanding fibrin-specific plasminogen activation was key to its therapeutic potential.
Animal models and initial patient treatments paved the way for clinical trials.

Findings:

Cloning and recombinant expression enabled large-scale production of t-PA.
Multicenter clinical trials demonstrated the therapeutic efficacy of t-PA.
t-PA has become a vital fibrin-specific thrombolytic agent.

Implications:

The development of t-PA revolutionized the treatment of thrombotic events.
Recombinant t-PA ensures widespread availability for clinical use.
Continued research may further refine thrombolytic therapies.